Please assess the completion status of the following clinical trial:

Trial Title: Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed endometrial cancer, including 1 of the following cellular types:~  * Endometrioid endometrial adenocarcinoma~ * Clear cell carcinoma~ * Papillary serous adenocarcinoma~ * Adenosquamous cell carcinoma~ * Other adenocarcinoma variant~* No carcinosarcoma~* Meets 1 of the following criteria:~  * Grade 3 carcinoma with \> 50% myometrial invasion (stage IC or IIA) (all papillary serous or clear cell carcinoma will be considered grade 3)~ * Grade 2 or 3 carcinoma with any cervical stromal invasion (stage IIB)~ * Known extra-uterine disease confined to the pelvis (stage III or IVA)~    * Patients with stage III or IVA disease must have undergone computed tomography (CT) scan or positron emission tomography (PET)/CT scan of the abdomen and pelvis within the past 56 days~* Has undergone hysterectomy (i.e., total abdominal, vaginal, robotic-assisted, radical, or laparoscopic-assisted vaginal hysterectomy) and bilateral salpingo-oophorectomy within the past 56 days~* No positive common iliac or positive para-aortic nodal disease (defined as lymph nodes ? 2 cm in any dimension on CT scan or biopsy) or positive peritoneal cytology~* No evidence of metastatic extrauterine disease, gross or residual disease (not including pelvic nodal disease), or distant metastases~* Zubrod performance status 0-1~* Absolute neutrophil count (ANC) ? 1,500/mm\^3 (without growth factor support)~* Platelet count ? 100,000/mm\^3~* Hemoglobin ? 10 g/dL (transfusion allowed)~* Total bilirubin ? 1.5 times upper limit of normal (ULN)~* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2 times ULN~* Serum creatinine ? 1.5 mg/dL~* Urine protein:creatinine ratio ? 0.5 OR urine protein \< 1,000 mg on 24-hour urine collection~* International normalized ratio (INR) \< 1.5 (for patients treated with warfarin within the past 14 days)~* Not nursing~* No neuropathy ? Common Terminology Criteria for Adverse Events (CTCAE) grade 1~* No ototoxicity \> CTCAE grade 2~* No serious, active comorbidity, including any of the following:~  * Unstable angina and/or New York Heart Association (NYHA) class II-IV congestive heart failure requiring hospitalization within the past 12 months~ * Transmural myocardial infarction within the past 12 months~ * Acute bacterial or fungal infection requiring IV antibiotics~ * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy~ * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects~ * Acquired immune deficiency syndrome (AIDS) based upon current Center for Disease Control (CDC) definition (human immunodeficiency virus \[HIV\] testing is not required)~ * Active gastrointestinal (GI) ulcers, GI bleeding, inflammatory bowel disease, or GI obstruction~ * Inadequately controlled hypertension, defined as systolic blood pressure (BP) \> 150 mm Hg and/or diastolic BP \> 90 mm Hg on antihypertensive medications~ * Significant vascular disease, including aortic aneurysm, aortic dissection, or arteriovenous malformation within the past 12 months~ * Serious cardiac arrhythmia on medication (well-controlled atrial fibrillation on medication allowed)~ * Serious non-healing wound, ulcer, or bone fracture~* No history of hypertensive crisis or hypertensive encephalopathy~* No stroke/cerebrovascular event within the past 12 months~* No arterial thromboembolic events, including transient ischemic attack or clinically symptomatic peripheral artery disease within the past 12 months~* No abdominal fistula, GI perforation, or intra-abdominal abscess within the past 6 months~* No other invasive malignancies within the past 3 years other than nonmelanomatous skin cancer~* No significant trauma within the past 28 days~* No mental status changes or bladder problems that would preclude the ability to comply with bladder-filling instructions~* No mental or psychiatric illness that would preclude giving informed consent~* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies~* No prior allergic reaction to bevacizumab, cisplatin, carboplatin, or paclitaxel~* No concurrent erythropoietin, St. John's wort, therapeutic anticoagulants, aminoglycoside antibiotics, or amifostine~* No prior organ transplantation~* No prior external-beam radiotherapy to the pelvis resulting in overlapping of radiotherapy fields~* No prior systemic chemotherapy for uterine cancer~  * Prior chemotherapy for a different cancer is allowed~* No prior therapy with anti-vascular endothelial growth factor (VEGF) compounds~* More than 28 days since prior major surgical procedure requiring open biopsy incision~* No concurrent surgery (except for vascular access device placement or procedures that do not require significant incision)~* No concurrent warfarin at doses \> 1 mg/day~  * Concurrent prophylactic low molecular weight heparin allowed

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (IMRT, cisplatin,bevacizumab,carboplatin,paclitaxel) (Type: EXPERIMENTAL): Patients undergo pelvic IMRT once daily, 5 days a week, for 5 weeks. Patients may also undergo optional nodal boost radiotherapy and/or vaginal brachytherapy boost. Patients also receive concurrent cisplatin IV over 1 hour on days 1 and 29 and bevacizumab IV over 30-90 minutes on days 1, 15, and 29. Beginning 4-6 weeks after completing IMRT, cisplatin, and bevacizumab, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Treatment with carboplatin and paclitaxel repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).